The divinity pharmaceutical industry rose nearly 10% DBS to maintain buying

Divinity Medicine (02877-HK) rose 9.25% a half-day, reported 6.38 Hong Kong dollars, a deal of HK $939600, the shares of the early run to win the index, the index rose 3.03%.　　The unit's early new highs to HK $6.38 have continued its recent strong trend. DBS maintained the stock's buying rating, while also raising its target price from HK $6 to HK $7.55, equivalent to 10 times times the 2009-year earnings ratio. The bank noted that revenues rose 27% per cent in the first quarter of 09 over a year earlier, higher than the bank's forecast for 22% per cent of the year, but the bank temporarily maintained its profit outlook unchanged. But it added that the profitability of the divinity pharmaceutical industry would rise, boosted by the size of the economy and the possible exchange-rate gains that the Aussie deposits could generate.